The RR (fixed effect) to develop any grade of ALT increase was 3.79 (95% CI, 2.89–4.98; p < 0.001) in advanced NSCLC patients received ALK-TKIs in comparison with chemotherapy (Q = 4.26, p = 0.12; I2 = 53.1%) (Figure 3A). This evidence concerns the gene ALK and non-small cell lung carcinoma.